[1] 2024 年 05 月 21 日药品批准证明文件送达信息. Retrieved May 21, 2024, from https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20240521135345169.html[2] Li N, Zhu J, Yin R, et al. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2023 doi: 10.1001/jamaoncol.2023.2283 [published Online First: 20230713].[3] 恒瑞医药创新药、PARP 抑制剂氟唑帕利新适应症上市申请获受理. Retrieved Aug 22, 2023, from https://mp.weixin.qq.com/s/4 hsnIM2Fva5KuDt-_2Qh-wx[4]2024 SGO|恒瑞创新药氟唑帕利再添晚期卵巢癌全人群一线维持治疗新证据. Retrieved Mar 20, 2024, from https://mp.weixin.qq.com/s/2NREhdpvmZ95KQfLjDeaQA